A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93

por Orr, Mark T., Beebe, Elyse A., Hudson, Thomas E., Moon, James J., Fox, Christopher B., Reed, Steven G., Coler, Rhea N.
Publicado 2014

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach

por Kramer, Ryan M, Archer, Michelle C, Orr, Mark T, Dubois Cauwelaert, Natasha, Beebe, Elyse A, Huang, Po-wei D, Dowling, Quinton M, Schwartz, Alicia M, Fedor, Dawn M, Vedvick, Thomas S, Fox, Christopher B
Publicado 2018

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

por Fox, Christopher B., Orr, Mark T., Van Hoeven, Neal, Parker, Sarah C., Mikasa, Traci J.T., Phan, Tony, Beebe, Elyse A., Nana, Ghislain I., Joshi, Sharvari W, Tomai, Mark A., Elvecrog, James, Fouts, Timothy R., Reed, Steven G.
Publicado 2016